FDA Approves Once-Monthly Omvoh Injection for Ulcerative Colitis Maintenance Therapy
Teh Food and Drug Administration (FDA) has granted approval for a revised dosing regimen of Eli Lilly’s Omvoh (mirikizumab-mrkz), transitioning to a convenient once-monthly injection for maintenance therapy in adult patients diagnosed with moderately to severely active ulcerative colitis.This approval streamlines treatment, replacing the previously required two-injection schedule.
This marks the third FDA approval this year for mirikizumab-mrkz, highlighting its growing role in the treatment of inflammatory bowel diseases. Prior approvals have demonstrated the efficacy and safety of Omvoh in Crohn’s disease, further solidifying its position as a valuable therapeutic option.
The updated approval provides patients with ulcerative colitis a less frequent injection schedule, potentially improving adherence and overall quality of life while maintaining effective disease control.
FDA Approves Once-Monthly Omvoh Injection for Ulcerative Colitis Maintenance Therapy
The Food and Drug Administration (FDA) has granted approval for a new, more convenient dosing regimen of Eli Lilly’s Omvoh (mirikizumab-mrkz) for the maintenance therapy of adult patients diagnosed with moderately to severely active ulcerative colitis. This approval streamlines treatment, transitioning from the previously required two-injection regimen to a single, once-monthly subcutaneous injection.
this marks the third FDA approval for mirikizumab, demonstrating its growing role in the treatment of inflammatory bowel diseases. Earlier approvals included indications for Crohn’s disease, further solidifying its efficacy and safety profile. The simplified dosing schedule is expected to improve patient adherence and overall quality of life by reducing the frequency of injections.
The approval is based on data demonstrating sustained clinical benefit and safety with the once-monthly administration, offering a valuable new option for individuals managing this chronic inflammatory condition. Healthcare professionals can now prescribe Omvoh with the assurance of a more patient-friendly treatment approach.